HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- ((6- (2- methoxyphenyl)pyrimidin- 4- yl)amino)phenyl)methane sulfonamide

a CDK9 inhibitor; structure in first source

Also Known As:

3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide; LDC000067; LDC067

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide: 4
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide: 4
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide: 4

Experts

1.	Cai, Yan: 1 article (01/2021)
2.	Chattipakorn, Nipon: 1 article (01/2021)
3.	Hu, Xiang: 1 article (01/2021)
4.	Huang, Shushi: 1 article (01/2021)
5.	Huang, Weijian: 1 article (01/2021)
6.	Liang, Guang: 1 article (01/2021)
7.	Luo, Wu: 1 article (01/2021)
8.	Qian, Jinfu: 1 article (01/2021)
9.	Shen, Qirui: 1 article (01/2021)
10.	Wu, Gaojun: 1 article (01/2021)

Related Diseases

1.	Inflammation (Inflammations) 01/01/2021 - "Further in vitro studies confirmed that LDC000067 and siRNA-mediated CDK9 knockdown reversed ox-LDL-induced inflammation and phenotypic switching of VSMCs from a contractile phenotype to a synthetic phenotype via inhibiting NF-κB signaling pathway in human VSMCs. " 01/01/2021 - "LDC000067 treatment significantly suppressed HFD-induced inflammation, proliferation and phenotypic switching of VSMCs, resulting in reduced atherosclerosis in the ApoE-/- mice, while had no effect on plasma lipids. "
2.	Bone Resorption 10/01/2019 - "Interestingly, this study demonstrated that LDC067 inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and bone resorption in vitro, and suppressed the expression of osteoclast-related marker genes such as cathepsin K (CTSK), tartrate-resistant acid phosphatase (TRAP), dendrite cell-specific transmembrane protein (DC-STAMP), V-ATPase D2, calcitonin receptor (CTR) and nuclear factor of activated T cells cytoplasmic 1 (NFATc1). "
3.	Atherosclerosis 01/01/2021 - "LDC000067 treatment significantly suppressed HFD-induced inflammation, proliferation and phenotypic switching of VSMCs, resulting in reduced atherosclerosis in the ApoE-/- mice, while had no effect on plasma lipids. "
4.	Osteolysis 10/01/2019 - "In keeping with the results obtained in vitro, inhibition of CDK9 with LDC067 was observed to delay subchondral osteolysis and substantially ameliorate LPS-induced osteolysis in murine calvaria. " 10/01/2019 - "LDC000067 suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced osteolysis in vivo."
5.	Neoplasms (Cancer) 01/01/2014 - "Cultures of mouse embryonic stem cells, HeLa cells, several cancer cell lines, along with cells from patients with acute myelogenous leukaemia were also used to investigate cellular responses to LDC000067. " 01/01/2014 - "At the molecular and cellular level, LDC000067 reproduced effects characteristic of CDK9 inhibition such as enhanced pausing of RNA polymerase II on genes and, most importantly, induction of apoptosis in cancer cells. "

Related Drugs and Biologics

1.	Small Interfering RNA (siRNA)
2.	Cathepsin K
3.	NFATC Transcription Factors
4.	Calcitonin Receptors (Calcitonin Receptor)
5.	Proteins (Proteins, Gene)
6.	Ligands
7.	Adenosine Triphosphatases (ATPase)
8.	Tartrate-Resistant Acid Phosphatase
9.	oxidized low density lipoprotein
10.	RNA Polymerase II (RNA Polymerase B)